Nycomed Seeks U.S. Partner To Promote Alvesco Asthma Inhaler And Intranasal Omnaris
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approved Alvesco to treat asthma in patients 12 and older Jan. 10, the Swiss pharma tells “The Pink Sheet” DAILY.
You may also be interested in...
Sepracor Plans Alvesco, Omnaris Drug Launches Following Acquisition From Nycomed
Sepracor’s 1,600-person sales force will promote the asthma and allergic rhinitis treatments.
Sepracor Plans Alvesco, Omnaris Drug Launches Following Acquisition From Nycomed
Sepracor’s 1,600-person sales force will promote the asthma and allergic rhinitis treatments.
Swiss Pharma Nycomed Agrees To Market NPS’ Gattex Ex-U.S.
NPS gets $35 million upfront, potential $150 million in milestones and double-digit royalties from Nycomed for Gattex.